C4 Therapeutics narrows Q2 net loss to $23.6 million from $26.0 million
C4 Therapeutics reported second-quarter 2026 revenue of $6.6 million, up slightly from $6.5 million a year earlier, and a net loss of $23.6 million, down from $26.0 million. Lower research and development and general and administrative expenses drove the smaller loss, and the company said its cash will fund operations to the end of 2028. Per-share loss fell to $0.18 from $0.37, but the weighted-average share count rose to about 130.7 million from 71.0 million.
Key points
- Q2 2026 revenue was $6.6 million, versus $6.5 million in Q2 2025, helped by the new Roche collaboration.
- R&D expense fell to $24.5 million from $26.2 million; G&A expense fell to $8.6 million from $8.8 million.
- Net loss per share was $0.18, compared with $0.37; weighted-average shares rose to 130,696,742 from 71,005,743.
- Cash, cash equivalents and marketable securities were $300.4 million at June 30, 2026, which the company expects to fund operations to the end of 2028.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.